

Shuibin Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5777190/publications.pdf>

Version: 2024-02-01

49
papers

6,592
citations

172386

29
h-index

189801

50
g-index

52
all docs

52
docs citations

52
times ranked

8426
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA biogenesis pathways in cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 321-333.	12.8	1,738
2	The m ⁶ A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. <i>Molecular Cell</i> , 2016, 62, 335-345.	4.5	1,148
3	mRNA circularization by METTL3 ^Δ eIF3h enhances translation and promotes oncogenesis. <i>Nature</i> , 2018, 561, 556-560.	13.7	498
4	Mettl1/Wdr4-Mediated m ⁷ G tRNA Methylome Is Required for Normal mRNA Translation and Embryonic Stem Cell Self-Renewal and Differentiation. <i>Molecular Cell</i> , 2018, 71, 244-255.e5.	4.5	276
5	Mettl3-mediated m ⁶ A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. <i>Nature Communications</i> , 2018, 9, 4772.	5.8	265
6	N ⁶ -methyladenosine regulates glycolysis of cancer cells through PDK4. <i>Nature Communications</i> , 2020, 11, 2578.	5.8	163
7	STING activation in cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7759-7771.	4.6	150
8	N ⁶ -methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer. <i>EBioMedicine</i> , 2019, 47, 195-207.	2.7	146
9	N ⁷ -Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. <i>Molecular Cell</i> , 2021, 81, 3339-3355.e8.	4.5	146
10	Dynamic m ⁶ A mRNA methylation reveals the role of METTL3-m ⁶ A-CDCP1 signaling axis in chemical carcinogenesis. <i>Oncogene</i> , 2019, 38, 4755-4772.	2.6	142
11	METTL1/WDR4-mediated m ⁷ G tRNA modifications and m ⁷ G codon usage promote mRNA translation and lung cancer progression. <i>Molecular Therapy</i> , 2021, 29, 3422-3435.	3.7	121
12	Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. <i>Bone Research</i> , 2018, 6, 11.	5.4	99
13	METTL1 promotes hepatocarcinogenesis via m ⁷ G tRNA modification ^Δ dependent translation control. <i>Clinical and Translational Medicine</i> , 2021, 11, e661.	1.7	89
14	Selective microRNA uridylation by Zcchc6 (TUT7) and Zcchc11 (TUT4). <i>Nucleic Acids Research</i> , 2014, 42, 11777-11791.	6.5	87
15	METTL1 ^Δ m ⁷ G ^Δ EGFR/EFEMP1 axis promotes the bladder cancer development. <i>Clinical and Translational Medicine</i> , 2021, 11, e675.	1.7	87
16	Nanovaccines for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1559.	3.3	76
17	N ⁷ -methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis. <i>Nature Communications</i> , 2022, 13, 1478.	5.8	71
18	Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N ⁶ -Methyladenosine mRNA Methylation ^Δ Dependent Mechanism. <i>Hepatology</i> , 2021, 74, 1339-1356.	3.6	62

#	ARTICLE	IF	CITATIONS
19	Heterogeneous microenvironmental stiffness regulates pro-metastatic functions of breast cancer cells. <i>Acta Biomaterialia</i> , 2021, 131, 326-340.	4.1	56
20	Nucleotide resolution profiling of m7G tRNA modification by TRAC-Seq. <i>Nature Protocols</i> , 2019, 14, 3220-3242.	5.5	51
21	Methyltransferases modulate RNA stability in embryonic stem cells. <i>Nature Cell Biology</i> , 2014, 16, 129-131.	4.6	44
22	m ⁶ A methyltransferase METTL3 promotes retinoblastoma progression via PI3K/AKT/mTOR pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12368-12378.	1.6	42
23	Identification of small molecule inhibitors of Zcchc11 TUTase activity. <i>RNA Biology</i> , 2015, 12, 792-800.	1.5	41
24	METTL1-mediated m7G methylation maintains pluripotency in human stem cells and limits mesoderm differentiation and vascular development. <i>Stem Cell Research and Therapy</i> , 2020, 11, 306.	2.4	41
25	CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells. <i>Oncogene</i> , 2018, 37, 1885-1895.	2.6	39
26	Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Hepatology</i> , 2023, 77, 1122-1138.	3.6	39
27	METTL3 attenuates proliferative vitreoretinopathy and epithelial-mesenchymal transition of retinal pigment epithelial cells via wnt/β-catenin pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4220-4234.	1.6	37
28	METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 333-346.	2.3	37
29	Brief Report: Blockade of Notch Signaling in Muscle Stem Cells Causes Muscular Dystrophic Phenotype and Impaired Muscle Regeneration. <i>Stem Cells</i> , 2013, 31, 823-828.	1.4	36
30	Proteomic and Functional Analyses Reveal the Role of Chromatin Reader SFMBT1 in Regulating Epigenetic Silencing and the Myogenic Gene Program*. <i>Journal of Biological Chemistry</i> , 2013, 288, 6238-6247.	1.6	34
31	A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 853-866.	5.7	31
32	METTL3-Mediated m6A Methylation Regulates Muscle Stem Cells and Muscle Regeneration by Notch Signaling Pathway. <i>Stem Cells International</i> , 2021, 2021, 1-13.	1.2	30
33	Long Noncoding RNA HOXA-AS3 Integrates NF-κB Signaling To Regulate Endothelium Inflammation. <i>Molecular and Cellular Biology</i> , 2019, 39, .	1.1	23
34	pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy. <i>Advanced Therapeutics</i> , 2020, 3, 2000083.	1.6	22
35	Mettl5 mediated 18S rRNA N6-methyladenosine (m6A) modification controls stem cell fate determination and neural function. <i>Genes and Diseases</i> , 2022, 9, 268-274.	1.5	21
36	Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells. <i>Oncogene</i> , 2019, 38, 5425-5439.	2.6	19

#	ARTICLE	IF	CITATIONS
37	Nucleic Acid Immunotherapeutics for Cancer. <i>ACS Applied Bio Materials</i> , 2020, 3, 2838-2849.	2.3	18
38	Notch signaling pathway mediates Doxorubicin-driven apoptosis in cancers. <i>Cancer Management and Research</i> , 2018, Volume 10, 1439-1448.	0.9	17
39	Methyltransferase 1 is required for nonhomologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy. <i>Hepatology</i> , 2023, 77, 1896-1910.	3.6	17
40	N ⁷ -methylguanosine (m ⁷ G) tRNA modification: a novel autophagy modulator in cancer. <i>Autophagy</i> , 2023, 19, 360-362.	4.3	12
41	Anti-tumor Drug THZ1 Suppresses TGF β ² -mediated EMT in Lens Epithelial Cells via Notch and TGF β ² /Smad Signaling Pathway. <i>Journal of Cancer</i> , 2019, 10, 3778-3788.	1.2	11
42	METTL1 limits differentiation and functioning of EPCs derived from human-induced pluripotent stem cells through a MAPK/ERK pathway. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 791-798.	1.0	10
43	Loss of m6A Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 852775.	1.1	10
44	Reduction-Induced Decomposition and Self-Aggregation Strategy To Induce Reactive Oxygen Species Generation for Cancer Therapy. <i>ACS Applied Bio Materials</i> , 2018, 1, 954-960.	2.3	8
45	METTL3-Mediated m6A RNA Modification Regulates Corneal Injury Repair. <i>Stem Cells International</i> , 2021, 2021, 1-14.	1.2	6
46	N6-methyladenosine (m6A) RNA modification in tumor immunity. <i>Cancer Biology and Medicine</i> , 2022, 19, .	1.4	6
47	mRNA alternative polyadenylation (APA) in regulation of gene expression and diseases. <i>Genes and Diseases</i> , 2023, 10, 165-174.	1.5	5
48	N6-methyladenosine (m6A) modification of ribosomal RNAs (rRNAs): Critical roles in mRNA translation and diseases. <i>Genes and Diseases</i> , 2023, 10, 126-134.	1.5	4
49	RNA epitranscriptomics: A promising new avenue for cancer therapy. <i>Molecular Therapy</i> , 2022, 30, 2-3.	3.7	3